{"id":810421,"date":"2025-02-07T07:57:51","date_gmt":"2025-02-07T12:57:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\/"},"modified":"2025-02-07T07:57:51","modified_gmt":"2025-02-07T12:57:51","slug":"neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\/","title":{"rendered":"Neuronetics Announces Pricing\u00a0of\u00a0$18 Million Underwritten Public Offering of Common Stock"},"content":{"rendered":"
\n

MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the \u201cCompany\u201d) today announced that it has priced its previously announced underwritten public offering of its common stock, comprised of 8,000,000 shares of common stock at a public offering price of $2.25 per share, resulting in gross proceeds of approximately $18 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.<\/p>\n

The Company has also granted to the underwriter a 30-day option to purchase up to an additional 1,200,000 shares of common stock at the public offering price per share, less underwriter discounts and commissions. All of the shares in the offering are being sold by the Company. The Company currently intends to use the net proceeds of this offering for general corporate purposes, including but not limited to sales and marketing, research and development activities, financing of potential acquisitions or establishment of healthcare practices, purchases of inventory, general and administrative matters, working capital and capital expenditures. The offering is expected to close on or about February 10, 2025, subject to the satisfaction of customary closing conditions.<\/p>\n

Canaccord Genuity LLC is acting as sole bookrunner in connection with the offering.<\/p>\n

A shelf registration statement relating to the shares of common stock being sold in this offering was previously filed with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d) on November 9, 2022 and was declared effective on November 14, 2022. The offering is being made by means of a prospectus supplement and the accompanying prospectus that form part of the registration statement. A final prospectus supplement relating to and describing the final terms of the offering will be filed with the SEC and will be available on the SEC’s website located at http:\/\/www.sec.gov. When available, copies of the final prospectus supplement can be obtained from Canaccord Genuity LLC, Attention: Syndication Department, One Post Office Square, Suite 3000, Boston, Massachusetts 02109, or by telephone at (617) 371-3900, or by email at prospectus@cgf.com.<\/p>\n

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.\u00a0<\/p>\n

\n About Neuronetics<\/strong>\n <\/p>\n

Neuronetics, Inc. (\u201cNeuronetics\u201d) believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional\u00a0in-office\u00a0treatments that produce extraordinary results. NeuroStar Advanced Therapy (\u201cNeuroStar Therapy\u201d) is a\u00a0non-drug,\u00a0noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System (the \u201cNeuroStar System\u201d) and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (\u201cGreenbrook\u201d) treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (\u201cMDD\u201d) and other mental health disorders.<\/p>\n

NeuroStar Therapy is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also cleared by the U.S. Food and Drug Administration, as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15 to 21 with MDD. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results.<\/p>\n

\n \u201cSafe harbor\u201d statement under the Private Securities Litigation Reform Act of 1995:<\/strong>\n <\/p>\n

Certain statements in this press release, including the documents incorporated by reference herein, include \u201cforward-looking statements\u201d within the meaning of Section\u00a027A of the Securities Act of 1933, as amended (the \u201cSecurities Act\u201d), Section\u00a021E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and \u201cforward-looking information\u201d within the meaning of applicable Canadian securities laws. Statements in this press release that are not historical facts constitute \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as \u201coutlook,\u201d \u201cpotential,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cpredict,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould\u201d and \u201cshould\u201d as well as the negative of these terms and similar expressions. These statements include those relating to the contemplated public offering of common stock and the company\u2019s intended use of net proceeds from the offering. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to: market conditions and the completion of the public offering on the anticipated terms or at all, including the satisfaction of customary closing conditions related to the public offering; the effect of the transaction with Greenbrook, on the Company\u2019s business relationships, operating results and business generally; the Company\u2019s ability to execute its business strategy; the Company\u2019s ability to achieve or sustain profitable operations due to its history of losses; the Company\u2019s ability to successfully complete the announced restructuring plans; the Company\u2019s reliance on the sale and use of the NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of the Company\u2019s salesforce; the Company\u2019s ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using the Company\u2019s products; physician and patient demand for treatments using the Company\u2019s products; developments in competing technologies and therapies for the indications that the Company\u2019s products treat; product defects; the Company\u2019s revenue has been concentrated among a small number of customers; the Company\u2019s ability to obtain and maintain intellectual property protection for its technology; developments in clinical trials or regulatory review of the NeuroStar System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; the terms of the Company\u2019s credit facility; the Company\u2019s ability to successfully roll-out the Company\u2019s Better Me Provider program on the planned timeline; the Company\u2019s self-sustainability and existing cash balances; and the Company\u2019s ability to achieve cash flow break-even in the third quarter of 2025. For a discussion of these and other related risks, please refer to the Company\u2019s recent filings with the SEC, which are available on the SEC\u2019s website at www.sec.gov, including, without limitation, the factors described under the heading \u201cRisk Factors\u201d in Neuronetics\u2019 Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, and Greenbrook\u2019s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, as each may be updated or supplemented by subsequent reports that Neuronetics has filed or files with the SEC. These forward-looking statements are based on the Company\u2019s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company\u2019s expectations.<\/p>\n

\n Investor Contact:<\/strong>
\n
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com<\/p>\n

\n Media Contact:<\/strong>
\n
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the \u201cCompany\u201d) today announced that it has priced its previously announced underwritten public offering of its common stock, comprised of 8,000,000 shares of common stock at a public offering price of $2.25 per share, resulting in gross proceeds of approximately $18 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The Company has also granted to the underwriter a 30-day option to purchase up to an additional 1,200,000 shares of common stock at the public offering price per share, less underwriter discounts and commissions. All of the shares in the offering are being sold by the Company. The Company currently intends to … <\/p>\n

Continue reading “Neuronetics Announces Pricing\u00a0of\u00a0$18 Million Underwritten Public Offering of Common Stock”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-810421","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNeuronetics Announces Pricing\u00a0of\u00a0$18 Million Underwritten Public Offering of Common Stock - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neuronetics Announces Pricing\u00a0of\u00a0$18 Million Underwritten Public Offering of Common Stock - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the \u201cCompany\u201d) today announced that it has priced its previously announced underwritten public offering of its common stock, comprised of 8,000,000 shares of common stock at a public offering price of $2.25 per share, resulting in gross proceeds of approximately $18 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The Company has also granted to the underwriter a 30-day option to purchase up to an additional 1,200,000 shares of common stock at the public offering price per share, less underwriter discounts and commissions. All of the shares in the offering are being sold by the Company. The Company currently intends to … Continue reading "Neuronetics Announces Pricing\u00a0of\u00a0$18 Million Underwritten Public Offering of Common Stock"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-07T12:57:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDkyNyM2NzQxMDU0IzIxMTA0NDA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Neuronetics Announces Pricing\u00a0of\u00a0$18 Million Underwritten Public Offering of Common Stock\",\"datePublished\":\"2025-02-07T12:57:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\\\/\"},\"wordCount\":1249,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDkyNyM2NzQxMDU0IzIxMTA0NDA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\\\/\",\"name\":\"Neuronetics Announces Pricing\u00a0of\u00a0$18 Million Underwritten Public Offering of Common Stock - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDkyNyM2NzQxMDU0IzIxMTA0NDA=\",\"datePublished\":\"2025-02-07T12:57:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDkyNyM2NzQxMDU0IzIxMTA0NDA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDkyNyM2NzQxMDU0IzIxMTA0NDA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neuronetics Announces Pricing\u00a0of\u00a0$18 Million Underwritten Public Offering of Common Stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neuronetics Announces Pricing\u00a0of\u00a0$18 Million Underwritten Public Offering of Common Stock - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\/","og_locale":"en_US","og_type":"article","og_title":"Neuronetics Announces Pricing\u00a0of\u00a0$18 Million Underwritten Public Offering of Common Stock - Market Newsdesk","og_description":"MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the \u201cCompany\u201d) today announced that it has priced its previously announced underwritten public offering of its common stock, comprised of 8,000,000 shares of common stock at a public offering price of $2.25 per share, resulting in gross proceeds of approximately $18 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The Company has also granted to the underwriter a 30-day option to purchase up to an additional 1,200,000 shares of common stock at the public offering price per share, less underwriter discounts and commissions. All of the shares in the offering are being sold by the Company. The Company currently intends to … Continue reading \"Neuronetics Announces Pricing\u00a0of\u00a0$18 Million Underwritten Public Offering of Common Stock\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-07T12:57:51+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDkyNyM2NzQxMDU0IzIxMTA0NDA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Neuronetics Announces Pricing\u00a0of\u00a0$18 Million Underwritten Public Offering of Common Stock","datePublished":"2025-02-07T12:57:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\/"},"wordCount":1249,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDkyNyM2NzQxMDU0IzIxMTA0NDA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\/","name":"Neuronetics Announces Pricing\u00a0of\u00a0$18 Million Underwritten Public Offering of Common Stock - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDkyNyM2NzQxMDU0IzIxMTA0NDA=","datePublished":"2025-02-07T12:57:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDkyNyM2NzQxMDU0IzIxMTA0NDA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDkyNyM2NzQxMDU0IzIxMTA0NDA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-announces-pricing-of-18-million-underwritten-public-offering-of-common-stock\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Neuronetics Announces Pricing\u00a0of\u00a0$18 Million Underwritten Public Offering of Common Stock"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/810421","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=810421"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/810421\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=810421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=810421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=810421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}